Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence
Blood Vessels, Thrombosis & Hemostasis · 2026-11 · 3 (4) · 100223
DOI: 10.1016/j.bvth.2026.100223 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-11. Verfasst von Tomás José González-López und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Universitario de Burgos, Burgos, Spain. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Hematology Department, Hospital Universitario de Burgos, Burgos, Spain.
- Department of Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.
- Landsteiner Laboratory, Amsterdam University Medical Center Location University of Amsterdam, Amsterdam, The Netherlands.
Zitieren
APA
González-López, T. J., & Kapur, R. (2026). Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence. Blood Vessels, Thrombosis & Hemostasis, 3(4), 100223. https://doi.org/10.1016/j.bvth.2026.100223
Vancouver
González-López TJ, Kapur R. Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence. Blood Vessels, Thrombosis & Hemostasis. 2026;3(4):100223. doi:10.1016/j.bvth.2026.100223
BibTeX
@article{GonzlezLpez2026,
author = {González-López, Tomás José and Kapur, Rick},
title = {Bruton’s tyrosine kinase inhibitors in primary immune thrombocytopenia: pathophysiology and clinical evidence},
journal = {Blood Vessels, Thrombosis & Hemostasis},
year = {2026},
volume = {3},
number = {4},
pages = {100223},
doi = {10.1016/j.bvth.2026.100223}
}
EUVIMED